Catch a vibe: A PrEP study for HIV prevention
This study looks at how well long-acting injectable PrEP (a shot that prevents HIV) works for people who are at risk for HIV. Researchers want to understand the experience of patients and the healthcare staff who support them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You do not have HIV and are at risk for HIV infection
- You are starting or already on long-acting injectable PrEP (the prevention shot)
- You identify as a Black or Latinx cisgender woman, a Black or Latinx man who has sex with men, or as a transgender or nonbinary person
- You live in New York State and speak English or Spanish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a program combining counseling and support can help more Black men in New York City get tested for HIV and start using PrEP or PEP (medicines that prevent HIV). If you are a Black man who has sex with men and are not living with HIV, this trial may be a good fit.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
Hear when a new Health-Related Social Needs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.